Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2004
G-CSF: boosting endogenous production--a new strategy?Sonja von Aulock, Isabel Diterich, Lars Hareng, et al.Infection and Immunity|June 24, 2003
Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppressionIsabel Diterich, Carolin Rauter, Carsten J Kirschning, et al.The Journal of Pharmacology and Experimental Therapeutics|November 12, 2003
Granulocyte colony-stimulating factor (filgrastim) treatment primes for increased ex vivo inducible prostanoid releaseSonja von Aulock, Eva-Maria Boneberg, Isabel Diterich, et al.Journal of Clinical Microbiology|January 5, 2002
Distribution of clinically relevant Borrelia genospecies in ticks assessed by a novel, single-run, real-time PCRCarolin Rauter, Rainer Oehme, Isabel Diterich, et al.British Journal of Clinical Pharmacology|October 24, 2008
Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposureUlrike Halbsguth, Katharina M Rentsch, Dominique Eich-Höchli, et al.Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosisCarolin Rauter, Markus Mueller, Isabel Diterich, et al.Journal of Clinical Microbiology|October 6, 2006
Identification of Borrelia burgdorferi ribosomal protein L25 by the phage surface display method and evaluation of the protein's value for serodiagnosisMarkus Mueller, Sebastian Bunk, Isabel Diterich, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme diseaseNicolas W J Schröder, Isabel Diterich, Antje Zinke, et al.Pageof 1